Glenmark Pharma
Bookmark
ShareCopied to clipboardGlenmark Pharma is a company. It is a public company in Mumbai, India. It was founded in 1977 and its current CEO is Glenn Mario Saldanha. It is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Mumbai
- country: India
- employees: 14,989 people
- revenues: 1.6B $
- company type: public
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1977
- CEO: Glenn Mario Saldanha
- CEO approval: 89 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Glenmark Pharma:
Dataset of stocks from Glenmark Pharma:
Glenmark Pharma is one of the companies in India, companies in Pharmaceuticals, companies in Health Care, companies in Mumbai and 3,456,808 companies in our database.
Talking Points
- GlenmarkWelcome to Glenmark Pharmaceuticals
- Glenmark Pharma is discovering advance therapies for a new world. We are creating centers of excellence in dermatology, oncology and...
- Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide. Our vision is to discover possibilities and make lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted ...
- Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.